论文部分内容阅读
目的观察炔雌醇环丙孕酮片(商品名:达英-35,拜耳先灵医药公司生产)治疗面部自身免疫性孕酮皮炎的临床疗效和安全性。方法入选的32例面部自身免疫性孕酮皮炎患者,在月经第1天开始口服达英-35,每天1片(含醋酸环丙孕酮2mg和炔雌醇0.035mg),连用21d并停用7d为1个疗程,共治疗6个疗程。急性发作期患者同时予西替利嗪片等抗组胺药物口服治疗。自开始用药后第2,4和6个疗程时及停药后第2个疗程时进行随访。结果无脱落病例。治疗第2个疗程时症状体征明显缓解,治疗第2,4和6疗程末其有效率分别为65.63%,84.38%和93.75%。治疗结束后2个疗程时,有2例患者复发,复发率为6.25%。治疗期间有3例患者出现月经紊乱,后随着继续治疗均已逐渐恢复正常;停药后第2个疗程时仅2例患者出现病情反复,但均较治疗前减轻。余未见其他不良反应。结论达英-35治疗面部自身免疫性孕酮皮炎安全而有效。
Objective To observe the clinical efficacy and safety of ethinyl estradiol cyproterone tablets (brand name: Darlene-35, manufactured by Bayer Schering Pharma) for the treatment of facial autoimmune progesterone dermatitis. Methods A total of 32 patients with facial autoimmune progesterone dermatitis were enrolled in this study. One day a day (containing 2 mg of cyproterone acetate and 0.035 mg of ethinyl estradiol) orally darun-35 was administered orally once daily for 21 days and stopped 7d for a course of treatment, a total of 6 courses of treatment. Patients with acute exacerbation of the same time cetirizine tablets and other antihistamines oral treatment. Patients were followed up on the 2nd, 4th, and 6th courses of treatment and the second course of treatment after discontinuation. Results without shedding cases. Symptoms and signs were relieved on the second course of treatment, and the effective rates at the end of treatment 2, 4 and 6 were 65.63%, 84.38% and 93.75% respectively. Two courses of treatment after the end of 2 cases of relapse, the recurrence rate was 6.25%. During the treatment period, 3 patients had menstrual disorders, and then gradually returned to normal with continued treatment. Only 2 patients in the second course of treatment discontinued the disease, both of which were less severe than those before treatment. I have seen no other adverse reactions. Conclusion Darlene-35 treatment of facial autoimmune progesterone dermatitis safe and effective.